Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial.

ABSTRACT:

SUBMITTER: Lu S 

PROVIDER: S-EPMC12151220 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature